The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023

Table of Contents

1 Executive Summary: India' s Pharmaceutical Sector 2008-2023

• 1.1 Prospects for India' s Pharmaceutical Market
• 1.2 Aim, Scope and Format of the Report

2 Introduction to India' s Pharmaceutical Sector

• 2.1 Historical Developments and Prospects for India' s Pharmaceutical Sector
  • 2.1.1 India' s Early Years before 1970
  • 2.1.2 Impetus for Increased Domestic Production 1970s
  • 2.1.3 Development Phase 1980s and Growth Phase 1990s
  • 2.1.4 Indian Pharmaceutical Industry Status in 2000s
• 2.3 Foreign Policy of India Related to Pharmaceutical Sector
• 2.4 India' s GDP to Grow Significantly
• 2.5 India' s Market Abroad
• 2.6 India' s Purchasing Power Parity
• 2.7 Disease Epidemiology
  • 2.7.1 Malaria
  • 2.7.2 TB
  • 2.7.3 HIV/AIDS
  • 2.7.4 Pneumonia
  • 2.7.5 Diarrhoea
  • 2.7.6 Cancer
  • 2.7.7 Cardiovascular Diseases
  • 2.7.8 Diabetes
  • 2.7.9 Asthma and Bronchitis
  • 2.7.10 Neurological and Psychiatric Disorders and Addictions
• 2.8 Trend in Market for Individual Therapeutic Area

3 Analysis of the Indian Pharmaceutical Market

• 3.1 Pharmaceutical Market Analysis
• 3.2 Estimated Market Value for India' s OTC Market
• 3.3 Estimated Market Value for India' s Prescription Market
• 3.4 Estimated Market Volume for India' s Generic Market
• 3.5 Branded Products Will Take Significant Market Share from 2008 to 2023
• 3.6 India' s Major Selling Medicines
• 3.7 Sales Figure for Major Therapeutics Areas
• 3.8 Forecasts for Major Therapeutics Market: Anti-Infective
• 3.9 Forecasts for Major Therapeutics Market: Other Than Anti-Infective
• 3.10 Growth Rate in India' s Therapeutic Market

4 Contract Manufacturing Businesses in India

• 4.1 Forecasts for Contract Manufacturing Services
• 4.2 Contract Manufacturing in India
  • 4.2.1 Drivers for Contract Manufacturing for Outsourcing to India
• 4.3 Contract Manufacturing and Role of Indian Companies
  • 4.3.1 Outsourcing for Generics
  • 4.3.2 Sourcing Generics from Non-Competitors
  • 4.3.3 Divi' s Laboratories' Business Model
  • 4.3.4 Granules India for Production of Generic Prescription Medicines and OTCs
  • 4.3.5 Matrix Contract Manufacturer for CNS Products
  • 4.3.6 Neuland Focused on Anti-Bacterials
  • 4.3.7 Natco Chose Chronic Diseases
• 4.4 Enforcing GMP Compliance for APIs in EU
• 4.5 Growth in Biotechnology Sector of India
  • 4.5.1 Ranbaxy' s Entry Into Biotechnology

5 Contract Research Businesses in India

• 5.1 Forecasts for Contract Research
• 5.2 Focus on Innovative R&D
• 5.3 CROs to Maintain High Quality
• 5.4 Drivers and Restrains for Outsourcing Clinical Research Services from India
• 5.5 Contract Research and Companies
  • 5.5.1 R&D Investments by Foreign MNCs in India
  • 5.5.2 Vimta is an Emerging Company
  • 5.5.3 Suven is Emerging as a Contract R&D Focused
  • 5.5.4 Wellquest is a CRO Compliant with International Regulatory Norms
• 5.6 Outsourcing Clinical Data Management
  • 5.6.1 GlaxoSmithKline to Outsource Data Management
  • 5.6.2 Clininvent is a CRO with Standardised Data Management Skills
• 5.7 Emerging Outsourcing Models
• 5.8 National Drug Authority to be Formed
• 5.9 Firsthand Interview for Expert Opinion on Clinical Research 1
  • 5.9.1 Small and Medium Sized Companies Opt For CROs
  • 5.9.2 Pros and Cons of Contract Research Services from India
  • 5.9.3 India' s Own Innovative Products
  • 5.9.4 Differences between India and China for Undertaking Trials
• 5.10 Firsthand Interview for Expert Opinion on Clinical Research 2
  • 5.10.1 Asian Nations with Proven Efficacy to Undertake Clinical Trials
• 5.11 Firsthand Interview for Expert Opinion on Clinical Research 3
  • 5.11.1 Pros and Cons of Contract Research Services from India

6 India' s Pharmaceutical Company Profile and Opportunities with Them

• 6.1 Suitable Business Models for Individual Pharmaceutical Companies in India
  • 6.1.1 Merger and Acquisition (M&A) for Indian Companies
    • 6.1.1.1 Dr Reddy Acquires Betapharm
  • 6.1.2 Indian Pharmaceutical Companies Enter World Market
    • 6.1.2.1 Zyday Cadila
    • 6.1.2.2 Sun
    • 6.1.2.3 Alkem
    • 6.1.2.4 Wockhardt
    • 6.1.2.5 Lupin
    • 6.1.2.6 Ranbaxy
    • 6.1.2.7 Cipla
  • 6.1.3 Collaboration for Expansion and Improvement
  • 6.1.4 Good Manufacturing Practice (GMP) Compliance
  • 6.1.5 Foreign MNCs Maintain Significant Market Share in India
    • 6.1.5.1 GlaxoSmithKline' s Significant Market Share in India
    • 6.1.5.2 Pfizer Emerged as the Most Significant Pharmaceutical Patent Applicant in India

7 SWOT Analysis for India' s Pharmaceutical Market

• 7.1 The Existing Advantages of India' s Pharmaceutical Sector
• 7.2 Vision for India' s Pharmaceutical Sector
• 7.3 Goal of India' s Pharmaceutical Sector
• 7.4 Visiongain Suggests Following Strategies for India' s Pharmaceutical Sector
• 7.5 Drivers and Restrain for India' s Pharmaceutical Sector
• 7.6 India' s Changing Demographic Profile
  • 7.6.1 Public Healthcare System
  • 7.6.2 Private Sector Contribution to Healthcare
  • 7.6.3 Uneven Distribution of Healthcare
• 7.7 India' s Pricing Pattern for Pharmaceutical Industry
  • 7.7.1 Private Spending for Healthcare
  • 7.7.2 Wholesale Distribution and Price Regulation
• 7.8 Firsthand Interview for Expert Opinion 1
  • 7.8.1 Bureaucracy as Obstacles
  • 7.8.2 Improving Access to Rural Areas
  • 7.8.3 Therapeutic Areas to Get Increased Attention from 2008 to 2023
  • 7.8.4 Drug Resistance for Antibiotics as Unmet Needs
• 7.9 Firsthand Interview for Expert Opinion 2
  • 7.9.1 India' s Key Strength
  • 7.9.2 India' s Edge Over China In Pharmaceutical Business
  • 7.9.3 Need for Routine Inspection of Outsourcing Sites
  • 7.9.4 Need for Creation of Economic Zone for Pharmaceutical Industry
  • 7.9.5 Business Approach Needed for Rural Mass
  • 7.9.6 India as an Emerging Market
  • 7.9.7 Growth of India' s Medical Tourism
  • 7.9.8 Tropical Diseases Widespread in India
  • 7.9.9 Vertical Integration Recommended for India' s Companies
  • 7.9.10 India' s Emergence as a Major Pharmaceutical Market

8 Conclusions

• 8.1 India' s Progress in Healthcare
• 8.2 Increases in Demand for Private Healthcare
• 8.3 Increases in Patient Demand for Service Provision
• 8.4 India' s Progress in Pharmaceuticals and Outsourcing Services
• 8.5 Recommendations for India' s Pharmaceutical Sector
• 8.6 Recommendations to Foreign Pharmaceutical Companies for India' s Market

Tables

• Table 1.1 Forecasts for India' s Pharmaceutical Industry' s Market, 2008, 2013, 2018 & 2023
• Table 3.1 Pharmaceutical Sales ($bn) of Top 20 Nations, 2006
• Table 3.2 India' s Total Pharmaceutical Sales ($m), 2008-2014
• Table 3.3 India' s Total Pharmaceutical Sales ($m), 2015-2023
• Table 3.4 Forecasts for India' s Pharmaceutical Industry' s Market, 2008, 2013, 2018 & 2023
• Table 3.5 Forecasts for India' s International OTC Market ($m), 2006- 2014
• Table 3.6 Forecasts for India' s International OTC Market ($m), 2015-2023
• Table 3.7 Forecasts for India' s Domestic OTC Market,($m), 2006-2014
• Table 3.8 Forecasts for India' s Domestic OTC Market ($m), 2015-2023
• Table 3.9 Forecasts for India' s Prescription Market ($m), 2006-2014
• Table 3.10 Forecasts for India' s Prescription Market ($m), 2015-2023
• Table 3.11 Forecasts for Cephalosporins Sales ($m), 2006-2014
• Table 3.12 Forecasts for Cephalosporins Sales( $m), 2015-2023
• Table 3.13 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006-2014
• Table 3.14 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015-2023
• Table 3.15 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
• Table 3.16 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
• Table 3.17 Forecasts for Macrolides Sales ($m), 2006-2014
• Table 3.18 Forecasts for Macrolides Sales ($m), 2015-2023
• Table 3.19 Forecasts for Anti-Malarial Sales ($m), 2006-2014
• Table 3.20 Forecasts for Anti-Malarial Sales($m), 2015-2023
• Table 3.21 Forecasts for Anti-TB Sales ($m), 2006-2014
• Table 3.22 Forecasts for Anti-TB Sales ($m), 2015 -2023
• Table 3.23 Forecasts for Anti-Diarrhoeal Sales($m), 2006-2014
• Table 3.24 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
• Table 3.25 Forecasts for Amoebicides Sales($m), 2006-2014
• Table 3.26 Forecasts for Amoebicides Sales ($m), 2015-2023
• Table 3.27 Forecasts for NSAID Sales ($m), 2006-2014
• Table 3.28 Forecasts for NSAID Sales ($m), 2015-2023
• Table 3.29 Forecasts for H2 Receptor Blockers Sales($m), 2006-2014
• Table 3.30 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
• Table 3.31 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
• Table 3.32 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
• Table 3.33 Forecasts for Anti-Tussives Sales ($m), 2006-2014
• Table 3.34 Forecasts for Anti-Tussives Sales ($m), 2015-2023
• Table 3.35 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014
• Table 3.36 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023
• Table 3.37 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
• Table 3.38 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
• Table 3.39 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
• Table 3.40 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
• Table 3.41 Forecasts for Expectorants Sales ($m), 2006-2014
• Table 3.42 Forecasts for Expectorants Sales ($m), 2015-2023
• Table 3.43 Forecasts for Topical Corticosteroids Sales ($m), 2006-2014
• Table 3.44 Forecasts for Topical Corticosteroids Sales ($m), 2015-2023
• Table 3.45 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014
• Table 3.46 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023
• Table 3.47 Forecasts for Antacid Sales ($m), 2006-2014
• Table 3.48 Forecasts for Antacid Sales ($m), 2015 -2023
• Table 3.49 Forecasts for Calcium Sales ($m), 2006-2014
• Table 3.50 Forecasts for Calcium Sales ($m), 2015 -2023
• Table 3.51 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
• Table 3.52 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
• Table 3.53 Forecasts for Anti-Histamine Sales ($m), 2006-2014
• Table 3.54 Forecasts for Anti-Histamine Sales ($m), 2015-2023
• Table 3.55 Forecasts for Anti-Depressant Sales ($m), 2006-2014
• Table 3.56 Forecasts for Anti-Depressant Sales ($m), 2015-2023
• Table 4.1 Forecasts for India' s Contract Manufacturing Revenues ($m), 2006-2014
• Table 4.2 Forecasts for India' s Contract Manufacturing Revenues ($m), 2015-2023
• Table 5.1 Forecasts for India' s Contract Research Revenues ($m), 2006-2014
• Table 5.2 Forecasts for India' s Contract Research Revenues( $m), 2015-2023
• Table 5.3 Dr Reddy' s Pipeline Strength
• Table 6.1 Fastest Growing Local Companies from Top 50 in India
• Table 6.2 Leading Local Companies from Top 100 in India
• Table 6.3 Leading Corporate Groups
• Table 6.4 Merger and Acquisition Activities of Indian Companies, 2007
• Table 6.5 International M&A of Indian Firms
• Table 7.1 SWOT Analysis for India' s Pharmaceutical Sector
• Table 7.2 India' s Demographic Profile, 2007

Figures

• Figure 1.1 Forecasts for India' s Pharmaceutical Industry' s Market ($m), 2008, 2013,2018 & 2023
• Figure 2.1 Developments and Prospects for India' s Pharmaceutical Sector (Past,Present & Future)
• Figure 2.2 India' s Pharmaceutical Industry Culture and Attributes Figure 3.1 Countries Ranked by Pharmaceutical Market Share, 2006
• Figure 3.2 Ratio of Domestic Pharmaceutical Market Share by Value with Export,2006
• Figure 3.3 India' s Total Pharmaceutical Sales ($m), 2006-2014
• Figure 3.4 India' s Total Pharmaceutical Sales ($m), 2015-2023
• Figure 3.5 Forecasts for India' s Pharmaceutical Industry' s Market, 2008, 2013, 2018 & 2023
• Figure 3.6 Forecasts for India' s International OTC Market ($m), 2006-2014
• Figure 3.7 Forecasts for India' s International OTC Market ($m), 2015-2023
• Figure 3.8 Forecasts for India' s Domestic OTC Market ($m), 2006-2014
• Figure 3.9 Forecasts for India' s Domestic OTC Market ($m), 2015-2023
• Figure 3.10 Ratio for Domestic and International OTC Market Share ($m), India, 2006
• Figure 3.11 Forecasts for India' s Prescription Market ($m), 2006-2014
• Figure 3.12 Forecasts for India' s Prescription Market ($m), 2015-2023
• Figure 3.13 Proportion of India' s Generic Market Share by Volume in Global Market,2008
• Figure 3.14 Proportion of India' s Generic Market Share by Volume in Global Market,2023
• Figure 3.15 Ratio for Patent and Generic Market Share by Value, India, 2007
• Figure 3.16 Ratio for Patent and Generic Market Share by Value, India, 2023
• Figure 3.17 Major Anti-Infective Sales ($m), India, 2006
• Figure 3.18 Major Selling Prescription Medicines Other Than Anti-Infective ($m),India, 2006
• Figure 3.19 Major Selling OTC Medicines Other Than Anti-Infective ($m), India, 2006
• Figure 3.20 Ratio of Anti-Infective to Other Medicines in the Market, India, 2008
• Figure 3.21 Forecasts for Cephalosporins Sales ($m), 2006-2014
• Figure 3.22 Forecasts for Cephalosporins Sales ($m), 2015-2023
• Figure 3.23 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006- 2014
• Figure 3.24 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015- 2023
• Figure 3.25 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
• Figure 3.26 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
• Figure 3.27 Forecasts for Macrolides Sales ($m), 2006-2014
• Figure 3.28 Forecasts for Macrolides Sales ($m), 2015-2023
• Figure 3.29 Forecasts for Anti-Malarial Sales ($m), 2006-2014
• Figure 3.30 Forecasts for Anti-Malarial Sales ($m), 2015-2023
• Figure 3.31 Forecasts for Anti-TB Sales ($m), 2006-2014
• Figure 3.32 Forecasts for Anti-TB Sales ($m), 2015 -2023
• Figure 3.33 Forecasts for Anti-Diarrhoeal Sales ($m), 2006-2014
• Figure 3.34 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
• Figure 3.35 Forecasts for Amoebicides Sales ($m), 2006-2014
• Figure 3.36 Forecasts for Amoebicides Sales ($m), 2015-2023
• Figure 3.37 Forecasts for NSAIDs Sales ($m), 2006-2014
• Figure 3.38 Forecasts for NSAIDs Sales ($m), 2015-2023
• Figure 3.39 Forecasts for H2 Receptor Blockers Sales ($m), 2006-2014
• Figure 3.40 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
• Figure 3.41 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
• Figure 3.42 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
• Figure 3.43 Forecasts for Anti-Tussives Sales ($m), 2006-2014
• Figure 3.44 Forecasts for Anti-Tussives Sales ($m), 2015-2023
• Figure 3.45 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014
• Figure 3.46 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023
• Figure 3.47 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
• Figure 3.48 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
• Figure 3.49 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
• Figure 3.50 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
• Figure 3.51 Forecasts for Expectorants Sales ($m), 2006-2014
• Figure 3.52 Forecasts for Expectorants Sales ($m), 2015-2023
• Figure 3.53 Forecasts for Topical Corticosteroids Sales ($m), 2006- 2014
• Figure 3.54 Forecasts for Topical Corticosteroids Sales ($m), 2015- 2023
• Figure 3.55 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014
• Figure 3.56 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023
• Figure 3.57 Forecasts for Antacid Sales ($m), 2006-2014
• Figure 3.58 Forecasts for Antacid Sales ($m), 2015 -2023
• Figure 3.59 Forecasts for Calcium Sales ($m), 2006-2014
• Figure 3.60 Forecasts for Calcium Sales ($m), 2015 -2023
• Figure 3.61 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
• Figure 3.62 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
• Figure 3.63 Forecasts for Anti-Histamine Sales ($m), 2006-2014
• Figure 3.64 Forecasts for Anti-Histamine Sales ($m), 2015-2023
• Figure 3.65 Forecasts for Anti-Depressant Sales ($m), 2006-2014
• Figure 3.66 Forecasts for Anti-Depressant Sales ($m), 2015-2023
• Figure 3.67 Growth Rate According to Therapeutic Areas ($m), 2007
• Figure 4.1 Forecasts for India' s Contract Manufacturing Revenues ($m), 2008-2014
• Figure 4.2 Forecasts for India' s Contract Manufacturing Revenues ($m), 2015-2023
• Figure 4.3 Path Up the Value Chain for Indian Companies
• Figure 5.1 Forecasts for India' s Contract Research Revenues ($m), 2008-2014
• Figure 5.2 Forecasts for India' s Contract Research Revenues ($m), 2015-2023

Organisations Mentioned in the Report:

• Actavis
• Alkem
• Allen Spa
• Agency National for Vigilance Sanitaire (ANVISA)
• Advanced Medical Optics
• AstraZeneca
• Aurobindo
• Avecia
• Aventis
• Betapharm
• B-Tabs
• Bulk Drug Manufacturers Association
• Carbogen and Amcis
• Central Drugs Standards Control Organisation (CDSCO)
• Cipla
• Clininvent
• Dishman
• Divi' s
• Docpharma
• Dr. Reddy' s
• Elder
• Eli Lilly
• Emcure
• Ethimed
• FDA
• Geneva
• GlaxoSmithKline
• Government of India
• Granules India
• Hollister-Stier
• Indian Drug Manufacturers' Association
• IMS Health
• Ind-Swift
• Intas
• International Monetary Fund
• Johnson & Johnson
• Jubilant Organosys
• Lupin
• Macleods
• Mankind
• Matrix
• Medicamenta
• Medley
• Medicines and Healthcare products Regulatory Agency (MHRA)
• Medicines Control Council (MCC)
• Mundogen
• Mylan
• Natco
• National Institute of Pharmacy (NIP)
• Negma
• Neuland
• Nicholas Piramal
• Novartis
• Novo Nordisk
• Organisation of Pharmaceutical Producers of India (OPPI)
• Perigo
• Pfizer
• Pharmaceutical Inspection Convention (PIC)
• Pinewood
• Quintiles
• Ranbaxy
• Rexcel
• Rhodia
• Roche
• Sanmar API
• Sanofi-Aventis
• Shasun
• Solvay
• Sun
• Suven
• Taro
• Tata Consulting Services
• Terapia
• Therapeutic Goods Administration (TGA)
• Vimta
• Wellquest
• World Bank
• Wockhardt
• World Health Organisation (WHO)
• World Trade Organization (WTO)
• Zenotech
• Zuventus
• Zydus Cadila